BEEAF 2 Score: A New Risk Stratification Score for Patients With Stage B Heart Failure From the KUNIUMI Registry Chronic Cohort.

Autor: Odajima S; Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan., Fujimoto W; Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.; Department of Cardiology Hyogo Prefectural Awaji Medical Center Sumoto Japan., Takegami M; Department of Preventive Medicine and Epidemiology National Cerebral and Cardiovascular Center Suita Japan.; Department of Public Health and Health Policy, Graduate School of Medicine The University of Tokyo Japan., Nishimura K; Department of Preventive Medicine and Epidemiology National Cerebral and Cardiovascular Center Suita Japan., Iwasaki M; Department of Cardiology Hyogo Prefectural Awaji Medical Center Sumoto Japan., Okuda M; Department of Cardiology Hyogo Prefectural Awaji Medical Center Sumoto Japan., Konishi A; Clinical and Translational Research Center Kobe University Hospital Kobe Japan., Shinohara M; Division of Epidemiology Kobe University Graduate School of Medicine Kobe Japan., Nagao M; Division of Evidence-Based Laboratory Medicine Kobe University Graduate School of Medicine Kobe Japan., Toh R; Division of Evidence-Based Laboratory Medicine Kobe University Graduate School of Medicine Kobe Japan., Hirata KI; Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.; Division of Evidence-Based Laboratory Medicine Kobe University Graduate School of Medicine Kobe Japan., Tanaka H; Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.
Jazyk: angličtina
Zdroj: Journal of the American Heart Association [J Am Heart Assoc] 2024 Oct; Vol. 13 (19), pp. e034793. Date of Electronic Publication: 2024 Sep 30.
DOI: 10.1161/JAHA.124.034793
Abstrakt: Background: Stage B heart failure (HF) refers to structural heart disease without signs or symptoms of HF, so that early intervention may delay or prevent the onset of overt HF. However, stage B HF is a very broad concept, and risk stratification of such patients can be challenging.
Methods and Results: We conducted a prospective study of data for 1646 consecutive patients with HF from the KUNIUMI (Kobe University Heart Failure Registry in Awaji Medical Center) registry chronic cohort. The definition of HF stages was based on current guidelines for classification of 29 patients as stage A HF, 761 as stage B HF, 827 as stage C HF, and 29 patients as stage D HF. The primary end point was the time-to-first-event defined as cardiovascular death or HF hospitalization within 2.0 years of follow-up. A maximum of 6 adjustment factor points was assigned based on Cox proportional hazards analysis findings for the hazard ratio (HR) of independent risk factors for the primary end point: 1 point for anemia, estimated glomerular filtration rate <45 mL/min per 1.73 m 2 , brain natriuretic peptide ≥150 pg/mL, and average ratio of early transmitral flow velocity to early diastolic mitral annular velocity >14, and 2 points for clinical frailty scale >3. Patients with stage B HF were stratified into 3 groups, low risk (0-1 points), moderate risk (2-3 points), and high risk (4-6 points). Based on this scoring system (BEEAF 2 [brain natriuretic peptide, estimated glomerular filtration rate, ratio of early transmitral flow velocity to early diastolic mitral annular velocity, anemia, and frailty]), the outcome was found to become worse in accordance with risk level. High-risk patients with stage B HF and patients with stage C HF showed similar outcomes.
Conclusions: Our scoring system offers an easy-to-use evaluation of risk stratification for patients with stage B HF.
Databáze: MEDLINE
Externí odkaz: